0
2cureX signs yet another distribution agreement - this time with Omnigen Medical Products in Turkey
Press release d. 9. december 2021.
2cureX continues execution of its commercial strategy by expanding its distributor network and announced today that Omnigen will bring IndiTreat® products to Turkish patients and professionals.
2cureX and Omnigen have signed an agreement by which Omnigen becomes the distributor of IndiTreat® products in Turkey. Omnigen will be responsible for promoting IndiTreat® to Turkish oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.
Omnigen will initially focus on a series of world-class private hospitals located in Istanbul, where large hospital groups are candidates to use IndiTreat® to define the best therapy for each individual patient.
First commercial partner outside EU represents extra commercial opportunities
"This agreement with Omnigen allows us to address Turkey, a country with 84 million people and more than 20,000 new colorectal cancer cases per year" said Fernando Andreu, CEO of 2cureX. "Omnigen product portfolio is very complementary to IndiTreat® and we believe they are the perfect partner for 2cureX in Turkey".
"At Omnigen we are at the forefront of technology offering in oncology, and we think IndiTreat® tests fit perfectly to us" said Ali Kilinc, CEO of Omnigen. "Focusing first on the private hospital segment will help us build the momentum for a subsequent expansion to the general cancer patient population". And he continued: "Supporting therapy decision-making with drug sensitivity tests is a very important improvement for patients, and we are very much looking forward to starting the collaboration with 2cureX".
An international health hub attracting patients from all over the Region
"This is exciting news. Omnigen is an expert in high-end oncology solutions, with a strong, motivated and very well-connected team" said Jesper Floyd Kristiansen, VP Business Development at 2cureX. "Private hospitals in Turkey and especially in Istanbul receive patients from many other countries, looking for first class treatment, and the IndiTreat® tests will be a great match for the sophisticated offering in these hospitals".
The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.
About Omnigen
Omnigen is a well-established and nationwide supplier of Laboratory equipment and Molecular-Genetic testing in Turkey.
Omnigen has a strong relationship with the main cancer hospitals in Turkey both private and public. Due to this collaboration Omnigen is also in close contact with major pharma companies in Turkey
Omnigen has currently 15 employees, of which 12 have a university degree ensuring a high level of scientific support to customers.
For more information about Omnigen visit https://omnigen.com.tr
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, [email protected]
This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-09 08:45 CET.
OBS: 2cureX har betalt digital IR-aftale med ProInvestor.com
Press release d. 9. december 2021.
2cureX continues execution of its commercial strategy by expanding its distributor network and announced today that Omnigen will bring IndiTreat® products to Turkish patients and professionals.
2cureX and Omnigen have signed an agreement by which Omnigen becomes the distributor of IndiTreat® products in Turkey. Omnigen will be responsible for promoting IndiTreat® to Turkish oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.
Omnigen will initially focus on a series of world-class private hospitals located in Istanbul, where large hospital groups are candidates to use IndiTreat® to define the best therapy for each individual patient.
First commercial partner outside EU represents extra commercial opportunities
"This agreement with Omnigen allows us to address Turkey, a country with 84 million people and more than 20,000 new colorectal cancer cases per year" said Fernando Andreu, CEO of 2cureX. "Omnigen product portfolio is very complementary to IndiTreat® and we believe they are the perfect partner for 2cureX in Turkey".
"At Omnigen we are at the forefront of technology offering in oncology, and we think IndiTreat® tests fit perfectly to us" said Ali Kilinc, CEO of Omnigen. "Focusing first on the private hospital segment will help us build the momentum for a subsequent expansion to the general cancer patient population". And he continued: "Supporting therapy decision-making with drug sensitivity tests is a very important improvement for patients, and we are very much looking forward to starting the collaboration with 2cureX".
An international health hub attracting patients from all over the Region
"This is exciting news. Omnigen is an expert in high-end oncology solutions, with a strong, motivated and very well-connected team" said Jesper Floyd Kristiansen, VP Business Development at 2cureX. "Private hospitals in Turkey and especially in Istanbul receive patients from many other countries, looking for first class treatment, and the IndiTreat® tests will be a great match for the sophisticated offering in these hospitals".
The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.
About Omnigen
Omnigen is a well-established and nationwide supplier of Laboratory equipment and Molecular-Genetic testing in Turkey.
Omnigen has a strong relationship with the main cancer hospitals in Turkey both private and public. Due to this collaboration Omnigen is also in close contact with major pharma companies in Turkey
Omnigen has currently 15 employees, of which 12 have a university degree ensuring a high level of scientific support to customers.
For more information about Omnigen visit https://omnigen.com.tr
About 2cureX
2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.
The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.
According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, [email protected]
This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-09 08:45 CET.
OBS: 2cureX har betalt digital IR-aftale med ProInvestor.com
